Glial TNFα in the spinal cord regulates neuropathic pain induced by HIV gp120 application in rats

Wenwen Zheng1,2,3, Handong Ouyang1,4, Xuexing Zheng1,3, Shue Liu1,3, Marina Mata1, David J Fink1 and Shuanglin Hao1,3*

Abstract

Background: HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral neuropathy, affecting about 30% of people with acquired immune deficiency syndrome (AIDS). The symptoms of HIV-SN are dominated by neuropathic pain. Glia activation in the spinal cord has become an attractive target for attenuating chronic pain. This study will investigate the role of spinal TNFα released from glia in HIV-related neuropathic pain.

Results: Peripheral gp120 application into the rat sciatic nerve induced mechanical allodynia for more than 7 weeks, and upregulated the expression of spinal TNFα in the mRNA and the protein levels at 2 weeks after gp120 application. Spinal TNFα was colocalized with GFAP (a marker of astrocytes) and Iba1 (a marker of microglia) in immunostaining, suggesting that glia produce TNFα in the spinal cord in this model. Peripheral gp120 application also increased TNFα in the L4/5 DRG. Furthermore, intrathecal administration of TNFα siRNA or soluble TNF receptor reduced gp120 application-induced mechanical allodynia.

Conclusions: Our results indicate that TNFα in the spinal cord and the DRG are involved in neuropathic pain, following the peripheral HIV gp120 application, and that blockade of the glial product TNFα reverses neuropathic pain induced by HIV gp120 application.

Keywords: HIV pain, TNFα, glia

Background

Infection of the central nervous system with the human immunodeficiency virus type 1 (HIV-1) can lead to cognitive, motor and sensory disorders. HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral neuropathy, affecting about 30% of people with acquired immune deficiency syndrome (AIDS) [1,2]. The symptoms of HIV-SN are dominated by neuropathic pain [3,4]. The mechanisms underlying HIV-SN remain unclear. Astrocytosis and subsequent neuron death are two hallmarks of HIV infection in the central nervous system [5]. Direct infection of neurons by HIV is thought to be unlikely [6,7]; HIV-1 binds via the external envelope proteins (e.g., gp120) to the chemokine receptors CXCR4 and/or CCR5 (co-receptors of gp120) on the cells. Previous reports have suggested that gp120 application contributes to neurotoxicity in in vitro and nociceptive behaviour in rodents [8-11]. Indeed, it has been demonstrated that gp120 application is capable of producing pain when administered peripherally [12] or centrally [13]. Proposed mechanisms underlying gp120 application induced a chronic nociceptive effect included spinal gliosis [8]. HIV gp120 application might produce such effects indirectly, via an action on glial cells, causing them to release inflammatory cytokines [13].

Dysregulation of cytokines has been implicated in a variety of painful neurological diseases and in animal models of neuropathic pain. HIV-1 transgenic rats overexpressing gp120 induce reactive gliosis (in the
brain), a marker for central nervous system damage [14]. HIV virus infection is able to increase the production and utilization of several cytokines, such as TNFα and IL-1β [15]. Cerebrospinal fluid from most of the patients with AIDS has increased levels of TNFα [16]. A transgenic rat developed using an HIV-1 construct, with deleted gag and pol genes, shows a strikingly high expression of TNFα [17]. A mouse model of systemic HIV-1 infection increases expression of IL-1β [18]. The viral gp120 induces the release of TNFα and IL-1β whose interaction have synergistic activities [19]; TNFα and IL-1β upregulate HIV-1 expression in cells infected by HIV [20]. This may result in an HIV gp120-cytokines reciprocal amplification with potential deleterious effects (a positive feedback cycles) [19]. An elevated baseline of TNFα level among HIV-1 positive individuals, may lead to additional neurodegeneration [21]. However, the role of spinal cytokines in the neuropathic pain induced by gp120 is not clear. In the present study, we investigated the role of TNFα in the neuropathic pain induced by gp120 application into the sciatic nerve.

Results
Peripheral gp120 application induced mechanical allodynia
Before peripheral gp120 application (50 or 400 ng of gp120 in 250 μl of 0.1% RSA) into the sciatic nerve, the baseline of mechanical threshold was around 11 grams. After the gp120 application, mechanical threshold decreased significantly on the ipsilateral paw from day 5; mechanical threshold reached the lowest values at 2 weeks after gp120 application. In the sham group treated with RSA, rats showed no significant changes in mechanical threshold throughout the 7-week testing period. The difference in the threshold was very significant between the sham and gp120 application (50 ng), \( F(1,13) = 6.899, \ p < 0.02 \) vs sham, \( n = 7-8 \); high concentration of gp120 (400 ng) furthermore lowered the threshold, \( F(1,14) = 22.672, \ p < 0.001 \) vs sham, \( n = 7-9 \) (Figure 1). There is a significant difference between two doses of gp120, \( F(1,15) = 5.479, \ p < 0.05, \ n = 8 \), General linear model, repeated measured, SPSS.

Peripheral gp120 application upregulated the expression of TNFα mRNA in the spinal cord
Original studies show that a gp120 application into the sciatic nerve induced overexpression of spinal GFAP (a marker of astrocytes) and OX-42 (a marker of microglia) immunoreactivity, using immunoreactive density at the spinal dorsal horn at 5, 22 and 30 days after gp120 application [8,22]. In our behavioral study (Figure 1), we observed that allodynia reached the lowest value at 2 weeks, so in the current study we focused on a 2-week timepoint to investigate the neurochemical changes. We found that the gp120 application significantly increased expression of GFAP, Iba1 (a marker of microglia), and TNFα protein in

Figure 1 The time course of the mechanical threshold in the model of peripheral gp120 application. Rats exposed to perineural HIV-1 gp120 application (50 ng) developed a persistent, mechanical allodynia of the ipsilateral hind paw compared to the sham group, \( F(1,10) = 6.899, \ p < 0.021 \) vs sham, \( n = 7-8 \); HIV-1 gp120 application (400 ng) further induced mechanical allodynia of the ipsilateral hind paw, \( F(1,14) = 22.672, \ p < 0.001 \) vs sham, \( n = 7-9 \), General linear model, repeated measured, SPSS.

Peripheral gp120 application upregulated the expression of GFAP, Iba1 and TNFα
Previous studies show that a gp120 application into the sciatic nerve induced overexpression of spinal GFAP (a marker of astrocytes) and OX-42 (a marker of microglia) immunoreactivity, using immunoreactive density at the spinal dorsal horn at 5, 22 and 30 days after gp120 application [8,22]. In our behavioral study (Figure 1), we observed that allodynia reached the lowest value at 2 weeks, so in the current study we focused on a 2-week timepoint to investigate the neurochemical changes. We found that the gp120 application significantly increased expression of GFAP, Iba1 (a marker of microglia), and TNFα protein in
the spinal dorsal horn, compared to the sham group using Western blots (Figure 3). To our knowledge, we were the first to observe that the gp120 application increased expression of TNFα in the spinal dorsal horn.

**Examination of expression of TNFα in the spinal dorsal horn using immunohistochemistry in gp120 application-induced neuropathy**

Spinal gliosis occurs following perineural HIV-gp120 application [8,11]. A substantial increase in TNFα immunoreactive staining was observed in the ipsilateral L5 spinal cord. The most prominent increase was found in the medial lamina I-IV of the dorsal horn, but the deep dorsal horn (laminas V and VI) and the ventral horn also showed an increase in TNFα immunostaining (Figure 4). However, less immunostaining of spinal TNFα was seen in the contralateral side of the gp120 application. Triple-label immunostaining of GFAP, TNFα and NeuN was carried out. There was an almost complete colocalization between GFAP (blue) and TNFα (red) imaging, but TNFα did not colocalize with NeuN (green), which suggested that TNFα was located in astrocytes, but not neurons (Figure 5). Double-label immunostaining of Iba1 and TNFα in the spinal dorsal horn was carried out in rats treated with gp120 application for 2 weeks (Figure 6). There was marked colocalization between Iba1 and TNFα imaging, suggesting that TNFα may also be released from microglia.

**Peripheral gp120 application increased the expression of TNFα in the DRG**

Sensory DRG neurons play an important role in the regulation of nociceptive input transduction.

---

**Figure 4** Immunohistochemistry shows TNFα immunostaining in the whole spinal cord in rats with application of gp120 into the sciatic nerve. Fourteen days after gp120 application, a substantial increase in the intensity of TNFα immunostaining was observed in the ipsilateral L4/5 spinal cord. The most prominent increase was found in the medial lamina I-V of the dorsal horn, but the deep dorsal horn (laminas V and VI) and the ventral horn also showed an increase in TNFα immunostaining.

---

Previous studies show that nerve injury induces upregulation of TNFα in the DRG neurons [23,24]. In the study with cultured DRG cells, CXCR4 binding on Schwann cells by gp120 application results in the release of RANTES, which induces TNFα production by DRG neurons, and subsequent TNFR1-mediated neurotoxicity in an autocrine/paracrine fashion [9]. In the current

---

**Figure 3** The expression of spinal GFAP, Iba1, and TNFα in the gp120 application model. Two weeks after gp120 application, the left L4/5 spinal dorsal horns were harvested under anesthesia, and protein expression of spinal GFAP, Iba1, and TNFα was tested using Western blots. Perineural gp120 application significantly induced the upregulation of GFAP, Iba1, and TNFα in the spinal cord level. *p < 0.05 vs sham, **p < 0.01 vs sham, t test, n = 3-4.
study, we observed a clear TNFα immunostaining in the DRG in rats with gp120 application (Figure 7B) compared to the sham group (Figure 7A). We found that TNFα was significantly increased in the gp120 application compared to the sham group using Western blots (Figure 7C).

The antinociceptive effect of glial inhibitor on the gp120 application-induced mechanical allodynia
Furthermore, we investigated the antinociceptive effect of soluble TNF receptor on the gp120 application-induced mechanical allodynia. Soluble TNF receptor may block TNFα from binding to a membrane TNF receptor on the cell surface, to neutralize the biological effect of TNFα. Overexpression of soluble TNF receptor by HSV vectors reversed the increase in TNFα and mechanical allodynia in the neuropathic pain models [28,29]. At 2 weeks after gp120 application, intrathecal recombinant soluble TNF receptor or vehicle was administered 3 times at 12 hour intervals. Mechanical threshold was tested after the last injection. Mechanical threshold increased significantly at 30 and 60 min in rats with soluble TNF receptor, but not the vehicle (Figure 9A), $F(1, 11) = 10.808, p = 0.007, n = 6-7$, General linear model, repeated measure, SPSS.

TNFα siRNA knockdown in vitro and in vivo
We examined whether TNFα siRNA knockdown reversed the neuropathic pain induced by gp120 application. We used cultured glial cells to identify the efficacy of TNFα siRNA that we ordered. We have found that the LPS effectively stimulates HAPI cells (one of glial cell lines) to release TNFα [30]. HAPI cells were pretreated with TNFα siRNA or mismatch RNA for 24 hours, and then stimulated with LPS for 6 hours. The supernatant was collected for testing the expression of TNFα with an ELISA kit (R&D). Pretreatment with TNFα siRNA, but not mismatch RNA suppressed the model (Figure 8), $F_{(1,8)} = 13.650, p = 0.006, n = 5$, General Linear Model, repeated measure, SPSS, which was consistent with that reported in other neuropathic pain models [25,27].
expression of TNFα in the cultured medium (Figure 9B). In the control group without LPS, non TNFα was detected (data not shown). Intrathecal siRNA of TNFα or mismatch RNA (10 μg) was given 2 times at 12-hour intervals. Mechanical threshold was tested after the last injection, and increased significantly at 6 and 24 hours in rats with TNFα siRNA, but not the mismatch RNA (Figure 9C), *F*(1,12) = 20.293, *p* = 0.001, *n* = 7, General Linear Model, repeated measure with SPSS.
Discussion

Previous studies indicate that TNFα is involved in the development of chronic pain. There is growing evidence suggesting that glial activation plays an important role in the HIV-sensory neuropathy. The current study showed 1) that HIV gp120 application into the sciatic nerve induced neuropathic pain behavior, and upregulated the expression of spinal GFAP, Iba1, and TNFα; 2) that TNFα was colocalized with either GFAP or Iba1 in the spinal cord, suggesting that TNFα is released from the activated astrocytes or microglia; 3) that gp120 application also induced upregulation of TNFα in the DRG; and 4) that knockdown of TNFα with siRNA or recombinant soluble TNF receptor reversed mechanical allodynia induced by gp120 application.

Neuropathic pain is disorder resulting from damage or alteration to nerve structures in the absence of demonstrated tissue damage. HIV infection might influence the basic neurobiology, neurological morphology, and clinical management of neurological dysfunction [31-33]. The entry of HIV into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp120 (cleavage of gp160), with the CD4 glycoprotein and chemokine receptors on the cell surface [34-37], facilitating receptor signaling in both the peripheral nervous system and the CNS [36,38,39]. In in vitro studies, HIV-gp120 binding to Schwann cells through CXCR4 results in the release of RANTES, which induces TNFα production by DRG, and subsequent TNFRI-mediated neurotoxicity in an autocrine/paracrine fashion [9]. In in vivo studies, HIV-1 transgenic rats overexpressing gp120 induce reactive gliosis in brain [14]. Astrocyte activation or astrogliosis may directly contribute to HIV-associated neurological disorders [40]. Injection of gp120 into the hindpaws produces pain hypersensitivity by directly exciting primary nociceptive neurons [41]. Intrathecal injection of gp120 recombinant protein induces an acute painful behavior and proinflammatory cytokine release in the spinal cord [10]. Cerebrospinal fluid from most patients with AIDS shows an increase in TNFα [16]. The HIV gp120 induces the release of IL-1β and TNFα whose interaction has synergistic activities [19]. In clinic, TNFα has also been implicated in the pathogenesis of HIV-1 infection, promoting HIV replication in T cell lines and in lymphocytes in HIV-infected patients [42]. Serum concentrations of TNFα have been shown to increase as HIV-1 infection progresses [43], suggesting that TNFα may contribute to disease progression. Thus, inhibition of TNFα in the setting of HIV infection has been appealing, at least in theory. However, whether TNFα is involved in the development of neuropathic pain in the HIV/AIDS patients is not clear.

Inflammation of peripheral nerves causes sustained increased electrical activity in the C/Aδ fibers, that leads to transcriptional and post-translational changes in second order neurons in the spinal dorsal horn, that are characteristic of chronic pain [44]. Evidence indicates that peripheral nerve damage or inflammation, results in the activation of glia in the dorsal horn that plays an important role in the pathogenesis of neuropathic pain [45-47]. After peripheral nerve injury or spinal cord injury TNFα in spinal microglia or astrocytes is increased [28,29,46]. In the current study, we used the peripheral gp120 application model and also found similar results.

In the chronic constriction injury model of peripheral neuropathic pain, neutralizing antibodies to TNF and to TNFR1 reduce thermal hyperalgesia and mechanical allodynia [48], and intrathecal administration of the recombinant soluble TNFR (sTNFR) peptide (etanercept), prior to selective spinal nerve ligation reduces mechanical alldynia [40]. Administration of drugs that block the effects of these cytokines [24,49] or that block glial activation [50] can be used to prevent or reverse neuropathic pain, which is consistent with our results. Previous studies have shown that overexpression of spinal TNFα released from microglia and/or astrocytes play an important role in the different neuropathic pain models [28,29,51,52]. Our current study showed that TNFα in the DRG might also involve neuropathic pain in this model, which is consistent with previous reports [23,24].

Transmembrane TNFα, a precursor of the soluble form of TNFα (sTNFα), is expressed on activated macrophages and lymphocytes as well as other cell types (e.g., glia in the CNS). After processed by TNF-alpha converting enzyme, the soluble form of TNFα is cleaved from transmembrane TNFα and mediates its biological activities [53]. Although many studies demonstrate increased TNFα mRNA and/or protein in neuropathic pain, to our knowledge, none of those reports demonstrate the release of sTNFα in the spinal cord in models of persistent pain. In our previous studies of neuropathic pain induced by spinal cord injury [28], spinal nerve ligation [29], and of inflammatory pain [30], we have found by Western blot that there is an increase in full-length mTNFα (26 kD) without detectable sTNFα in the spinal dorsal horn. In the current study, we did not observe sTNFα either.

In summary, there is abundant evidence to suggest that one of the important elements is neuroimmune activation of glia and glial products in the spinal cord in the neuropathic pain state [54-56]. While the mechanisms underlying HIV-related neuropathic pain are poorly understood, the results of the current investigation provide an important insight into the pathogenesis of chronic pain. Other targets (e.g., IL-1β, p-p38) will be addressed in the near future.
Methods

Animal experiments
Male Sprague-Dawley rats weighing 225-250 g were housed one to three per cage approximately 7 days prior to the beginning of the study. Free access to food and water and maintained on a 12:12 light:dark schedule at 21°C and 60% humidity. All housing conditions and experimental procedures were approved by the University Animal Care and Use Committee and were conducted in accordance with the ethical guidelines of the International Association for the Study of Pain [57].

Intrathecal catheter implantation
For intrathecal administration, intrathecal catheters were implanted under isoflurane anesthesia [58]. A polyethylene (PE-10) catheter filled with 0.9% saline was advanced 8 cm caudally through an incision in the atlanto-occipital membrane to position its tip at the level of the lumbar enlargement. The rostral tip of the catheter was passed subcutaneously, externalized on top of the skull, and sealed with a stainless-steel plug. Animals showing neurological deficits after implantation were excluded. Animals were used within 5 days after implantation of the catheter.

Perineural gp120 application model
Under anesthesia, male Sprague-Dawley rats (225-250 grams) were used and the left sciatic nerve was exposed in the popliteal fossa without damaging the nerve construction. A 2 x 6 mm strip of oxidized regenerated cellulose was previously soaked in 250 μl of a 0.1% rat serum albumin (RSA) in saline, containing 50 or 400 ng of gp120 (Immunodiagnostics, Bedford, MA.) or 0.1% RSA in saline for the sham surgery. A length 3-4 mm of sciatic nerve (Immunodiagnostics, Bedford, MA.) or 0.1% RSA in saline, containing 50 or 400 ng of gp120 was previously soaked in 250 μl of a 0.1% rat serum albumin (GAPDH) and relative to a calibrator, is given by 2^-ΔΔCt, with ΔCt indicating the cycle number at which the fluorescence signal of the PCR product crosses an arbitrary threshold set within the exponential phase of the PCR, and ΔΔCt = [(Ct_target (unknown sample) - Ct_end.control (unknown sample))] - [(Ct_target (calibrator sample) + Ct_end.control (calibrator sample))] as previously described [61].

Western Blots
The tissues were homogenized in protein lysis buffer (150 mM sodium chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing protease inhibitors and phosphatase inhibitors (Phosphatase Inhibitor Cocktails 1/2, Sigma, St. Louis, MO, USA). The homogenate was centrifuged at 18,000 g for 20 min at 4°C. The supernatant was collected and assayed for protein concentration using the DC protein assay (Bio-Rad, Hercules, CA, USA). Aliquots containing 30 μg of protein were dissolved in Laemmli buffer and denatured at 95°C for 5 min; the proteins were separated by 10% Tris-glycine SDS-PAGE gel and transferred to a PVDF membrane. The membranes were blocked with 5% nonfat dry milk in PBS buffer, and then incubated with primary antibodies for 1 h at room temperature, including mouse anti-GFAP (1:10,000, von Frey filament was applied. Animals that did not respond to a pressure of 15.1 g were assigned to this cutoff value. The tactile stimulus producing a 50% likelihood of withdrawal was determined using the up-down method [59,60].

Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated from the spinal cord using TRIzol reagent (Invitrogen, Camarillo, CA, USA), treated with RNase-free DNase-I (Roche, Indianapolis, IN, USA) and re-purified, and then quantified spectrophotometrically. Total RNA (1 μg) was reverse transcribed (Omniscript RT kit, Qiagen, Valencia, CA, USA) using random hexamers PCR primer. cDNA prepared from mRNA was amplified using the following primer sets: GAPDH-forward 5’-GTTTGTGATGGGTGTAACC-3’ and -reverse 5’-TCTTTGAGTGCGATGATG-3’; TNFα-forward 5’-CTTCAAGGGCAGAAGCTG-3’ and -reverse 5’-GAGGCTGACTTTTCTCCTG-3’. PCR was performed with equal amounts of cDNA in the GeneAmp 7700 sequence detection system (Applied Biosystems, Foster City, CA, USA), using SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Reactions (total volume, 25 μl) were incubated at 95°C for 10 min, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Each sample was measured, and data points were examined for integrity by analysis of the amplification plot. The comparative cycle threshold (Ct) method was used for relative quantification of gene expression. The amount of mRNA, normalized to the endogenous control (GAPDH) and relative to a calibrator, is given by 2^-ΔΔCt, with Ct indicating the cycle number at which the fluorescence signal of the PCR product crosses an arbitrary threshold set within the exponential phase of the PCR, and ΔΔCt = [(Ct_target (unknown sample) - Ct_end.control (unknown sample))] - [(Ct_target (calibrator sample) + Ct_end.control (calibrator sample))] as previously described [61].
Sigma, St. Louis, MO, USA), rabbit anti-Iba1 antibody (1:1000, Wako, Richmond, VA), rabbit polyclonal anti-TNFα (1:500, Chemicon, Temecula, CA) and mouse anti-β-actin, (1:8000, monoclonal antibody, Sigma, St. Louis, MO, USA). The blots were incubated with secondary antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), developed in chemiluminescence solution (Thermo Scientific, Rockford, IL, USA). Quantification of Western blots was done from the obtained chemiluminescence values (BioRad, Hercules, CA, USA). Target protein bands were normalized using the amount of β-actin.

Immunohistochemistry
Immunohistochemical expression of GFAP, Iba1, TNFα and NeuN in the spinal cord in rats with gp120 treatment was investigated as described previously [62]. For immunofluorescence detection, cryosections were probed overnight with rabbit anti-GFAP polyclonal antibody (1:2000, DakoCytomation, Glostrup, Denmark), rabbit anti-Iba1 antibody (1:1000, Wako, Richmond, VA), goat anti-rat TNFα antibody (1:100; R&D systems, Minneapolis, MN), mouse anti-neuN monoclonal antibody (A60) (1:5000, Millipore, Billerica, MA), and then followed by incubation with complementary secondary antibodies labeled with blue-fluorescent Alexa Fluor 350, green-fluorescent Alexa Fluor 488, or red-fluorescent Alexa Fluor 594 (1:2000, Molecular Probes, Eugene, OR), 2 h at room temperature and photographed using a fluorescent microscope. Sections were selected and scanned using a Nikon fluorescence microscope.

Evaluation of the effect of TNFα siRNA in vitro
Glia cell line was used to verify the efficiency of TNFα siRNA in vitro. TNFα siRNAs (forward 5'-GCCCGU AGCCCAUGCUGUAAdTdT-3', reverse-5'-UACGACGUGGGCUACGGGCDTdT-3') and mismatch siRNA (forward-5'-GCCCGUAGAACACGUGUAAdTdT-3', reverse-5'-UACGACGUGUUUCACGGGCDTdT-3') were synthesized by Invitrogen (Invitrogen, CA, USA). We demonstrated that cultured HAPI cells (a glial cell line) treated with LPS, released TNFα [30]. In this study, HAPI cells were seeded into 6-well plates at 2 x 10⁵ cells/well 24 h before transfection. Transient transfection procedures were performed according to Lipofectamine RNAiMAX reagent instructions (Invitrogen, Carlsbad, CA, USA). Briefly, HAPI cells were incubated with 100 pmol siRNA and 6 μl Lipofectamine RNAiMAX complexes in Opti-MEM I reduced serum medium (Invitrogen, Carlsberg, CA, USA). Twenty four hours after siRNA application, cells were stimulated by 1 μg/ml of LPS (Sigma, St. Louis, MO, USA). Six hours after LPS, the supernatant was harvested and the concentration of TNFα was measured using an ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

Drugs and Data Analysis
Recombinant gp120 was purchased from Immunodiagnostics (Woburn, MA) and dissolved in 0.1% RSA. Soluble TNF receptor I was purchased from PeproTech and dissolved in 0.1% RSA. Pentoxifylline was purchased from Sigma (Sigma, St. Louis, MO) and dissolved in saline. The drug doses were selected on the basis of previous reports and our preliminary studies. To facilitate siRNA into cells, we used polyethyleneimine (PEI), a cationic polymer, as a delivery vehicle to prevent degradation and enhance cell membrane penetration of siRNA [63]. siRNA was dissolved in RNase-free water at the concentration of 1 μg/μl as a stock solution. Ten min before injection, 10 μl siRNA was mixed with 1.8 μl PEI. Intrathecal drugs were injected through the implanted polyethylene tubing (PE-10) within 10 μl followed by 10 μl of saline; the injection lasted 30 s by means of a Hamilton syringe.

The statistical significance of the differences was determined by the t test. The difference between the time-course curves of the behavioral testing was determined using a General Linear Model, repeated measure with SPSS. P-values of less than 0.05 were considered to be statistically significant.

Acknowledgements
This work was supported by grants from the NIH DA026734 (SH), DA025527 (SH), NS066792 and NIDDK DK044935 (DF and MM), Jilin University (WZ.), and China Scholarship Council (XZ).

Author details
1Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. 2Department of Animal Biotechnology, College of Animal Science and Veterinary Medicine, Jilin University, Changchun 130062, Jilin Province, P. R. China. 3Department of Anesthesiology, University of Miami Miller School of Medicine, Miami, FL33136, USA. 4Department of Anesthesiology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR China.

Authors’ contributions
WZ participated in RT-PCR, and Western blot. HO performed the surgery and behavioral testing. XZ was involved in siRNA and behavioral testing with HO. SL carried out sample collection and immunohistochemistry. MM and DF participated in the data analysis and interpretation. SH contributed to the experimental designs, the data analysis and interpretation, and wrote the manuscript. All authors reviewed and approved the final manuscript.

Competing interests
David Fink receives compensation for professional services from the University of Michigan and from the Department of Veterans Affairs. He also receives payments from the University of Pittsburgh for patents owned by the University on which he is a co-inventor. None of the other authors have received compensation for professional services or anticipate receiving such compensation in the near future.

Received: 21 February 2011 Accepted: 20 May 2011
Published: 20 May 2011

43. P Aukrust, NB Liabakk, F Muller, E Lien, T Espevik, SS Froland, Serum levels of tumour necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection—correlations to clinical, immunologic, and virologic parameters. J Infect Dis. 169, 420–424 (1994). doi:10.1093/infdis/169.2.420


